NetScientific UK Ltd.

About NetScientific UK Ltd.

NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on the United Kingdom and United States.

More information about NetScientific’s purpose, core strategy and investment model is available at


Fosun Pharma 

About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices, and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth.

For more information about Fosun Pharma, see: 


Drexel University

About Drexel University

Founded in 1891 in Philadelphia, Drexel is a comprehensive urban university of more than 24,000 students, and it is one of Philadelphia’s largest private employers. Drexel is a leader in experiential, technology-infused education, enriched by the nation’s premier cooperative- education program. The University’s research enterprise was recently elevated to R1 status in the Carnegie Classification of Institutions of Higher Education — a rank that denotes the highest level of research activity, held by just 37 private universities around the country. The University disclosed 84 total new inventions and received 36 new United States patents in fiscal year 2020.

For more information about Drexel University, see:


Baruch S. Blumberg Institute


About Blumberg Institute

The Baruch S. Blumberg Institute is an independent, nonprofit (501c3) research institute established in 2003 by the Hepatitis B Foundation to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. It is particularly focused on discovery of new therapeutics to manage chronic hepatitis B and liver cancer, and early detection of liver disease. Working with academic partners, its scientists have pioneered discovery of new strategies to manage chronic hepatitis B and to detect liver cancer. It was renamed in 2013 to honor Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus and co-founded the Hepatitis B Foundation. The Baruch S. Blumberg Institute created and manages the Pennsylvania Biotechnology Center, one of the nation’s leading incubators for life sciences startup companies..

For more information about Blumberg Institute see:




A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

INVESTORS | Glycotest Diagnostics